FivepHusion Collaborates with Treehill Partners and Syneos Health

5/26/23 3:13:09 AM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $SYNH alert in real time by email

FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, and Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, to develop and bring a novel, enhanced chemotherapeutic product to market.

Get the next $SYNH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SYNH

Date	Price Target	Rating	Analyst
2/13/2023	$30.00 → $28.00	Neutral → Underweight	JP Morgan
1/17/2023	$30.00 → $25.00	Overweight → Underweight	Barclays
1/13/2023	$25.00	Overweight → Underweight	Barclays
12/14/2022	$66.00 → $38.00	Buy → Neutral	Mizuho
11/7/2022	$55.00 → $27.00	Outperform → In-line	Evercore ISI
10/18/2022	$85.00 → $53.00	Overweight → Neutral	JP Morgan
9/14/2022		Buy → Neutral	Guggenheim
9/7/2022	$68.00	Neutral	UBS

More analyst ratings

Syneos Health Stockholders Approve Agreement with Private Investment Consortium
MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company's stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing o
8/2/23 8:47:45 AM ET
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion
Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management ("Elliott"), Patient Square Capital ("Patient Square"), and Veritas Capital ("Veritas") for $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt. The purchase price represents a
5/10/23 6:47:41 AM ET
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023
MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uni
4/13/23 4:31:00 PM ET
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care

$SYNH
Press Releases

Fastest customizable press release news feed in the world

Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
JERSEY CITY, N.J., April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in the United States (U.S.). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S. while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis. "For almost a decade, MT
4/29/24 9:00:00 AM ET
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight results from Phase 3 BouNDless trial in PD and real-world findings from preliminary analysis of RADICAVA® (edaravone) treatment in ALSJERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024. The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).
4/12/24 9:00:00 AM ET
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA's Orphan Drug program is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the U.S. Previously, the FDA granted RADIC
4/8/24 9:00:00 AM ET
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care

$SYNH
Leadership Updates

Live Leadership Updates

NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
2/27/24 9:00:00 AM ET
$BMRN
$ENOV
$OPCH
$SYNH
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Specialties
Medical/Nursing Services
Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector September 29, 2023 S&P MidCap 400 Addition Civitas Resources
9/26/23 5:41:00 PM ET
$CIVI
$HAYW
$SPGI
$SYNH
Oil & Gas Production
Energy
Industrial Machinery/Components
Industrials
Syneos Health Names Terttu Haring President, Clinical Sites & Patients
MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers. Under Dr. Haring'
9/26/23 7:30:00 AM ET
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care

FivepHusion Collaborates with Treehill Partners and Syneos Health

Chat with this insight

Recent Analyst Ratings for $SYNH

$SYNH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)

Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)

Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)

$SYNH Financials

Live finance-specific insights

Syneos Health Stockholders Approve Agreement with Private Investment Consortium

Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion

Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023

$SYNH SEC Filings

SEC Form 15-12G filed by Syneos Health Inc.

SEC Form 8-K filed by Syneos Health Inc.

SEC Form S-8 POS filed by Syneos Health Inc.

$SYNH Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

$SYNH Press Releases

Fastest customizable press release news feed in the world

Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.

Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting

Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)

$SYNH Leadership Updates

Live Leadership Updates

NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

$SYNH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$SYNH Market Insights

Live Market Insights

Syneos Health downgraded by JP Morgan with a new price target

Syneos Health downgraded by Barclays with a new price target

Syneos Health downgraded by Barclays with a new price target

Syneos Health Tapped PRA Health Sciences' Colin Shannon as the CEO Succeeding Michelle Keefe

Civitas Resources Set To Join S&P MidCap 400

Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity

Recent Analyst Ratings for
$SYNH

$SYNH
Insider Trading

$SYNH
Financials

$SYNH
SEC Filings

$SYNH
Large Ownership Changes

$SYNH
Press Releases

$SYNH
Leadership Updates

$SYNH
Analyst Ratings

$SYNH
Market Insights